Cidara Therapeutics to Report First Quarter 2025 Financial Results on May 8, 2025

Cidara Therapeutics to report Q1 2025 financial results on May 8, 2025, with a conference call at 5 PM ET.

Quiver AI Summary

Cidara Therapeutics, Inc. has announced that it will release its financial results for the first quarter of 2025 and provide operational highlights on May 8, 2025, following the U.S. market close. The company will hold a conference call and webcast at 5:00 PM Eastern Time to discuss these results and update on its business operations. Cidara is focused on developing drug-Fc conjugate immunotherapies using its Cloudbreak® platform, with its lead candidate, CD388, designed for long-lasting prevention of influenza. CD388 received Fast Track Designation from the FDA in June 2023, and enrollment for its Phase 2b trial was completed in December 2024. The company is also advancing other DFCs, including CBO421 for oncology, which received IND clearance in July 2024.

Potential Positives

Cidara Therapeutics will report its first quarter 2025 financial results and operational highlights, providing stakeholders with important information about the company's performance.
The lead DFC candidate, CD388, aims to achieve universal prevention of seasonal and pandemic influenza, which represents a significant advancement in public health and potential market impact.
CD388 was granted Fast Track Designation by the FDA, indicating a prioritized review process for this promising therapy.
The successful completion of Phase 2b enrollment for CD388 suggests positive momentum in the drug development process.

Potential Negatives

Failure to provide specific details on the financial results may indicate potential transparency issues or uncertainties in the company's performance.
The absence of any new major developments or partnerships mentioned in the release could reflect stagnation in company growth or innovation.
Potential reliance on a single lead DFC candidate (CD388) raises concerns about the company's diversification and risk management strategies.

FAQ

When will Cidara Therapeutics announce its Q1 2025 financial results?

Cidara Therapeutics will report its first quarter 2025 financial results on May 8, 2025.

What time is the Cidara conference call scheduled?

The conference call is scheduled for 5:00 PM Eastern Time on May 8, 2025.

How can I join the webcast for Cidara's financial results?

You can join the webcast through the link provided in the press release.

What is Cidara Therapeutics' lead DFC candidate?

Cidara's lead DFC candidate is CD388, aimed at preventing seasonal and pandemic influenza.

What designation did CD388 receive from the FDA?

CD388 was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) in June 2023.

Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.

$CDTX Insider Trading Activity

$CDTX insiders have traded $CDTX stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $CDTX stock by insiders over the last 6 months:

LESLIE TARI (CHIEF SCIENTIFIC OFFICER) sold 1,773 shares for an estimated $38,939
SHANE WARD (COO & CLO) sold 1,664 shares for an estimated $36,542

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$CDTX Hedge Fund Activity

We have seen 30 institutional investors add shares of $CDTX stock to their portfolio, and 7 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

TCG CROSSOVER MANAGEMENT, LLC added 1,005,901 shares (+inf%) to their portfolio in Q4 2024, for an estimated $27,038,618
VR ADVISER, LLC added 765,723 shares (+inf%) to their portfolio in Q4 2024, for an estimated $20,582,634
VIVO CAPITAL, LLC added 670,600 shares (+inf%) to their portfolio in Q4 2024, for an estimated $18,025,728
BVF INC/IL added 389,731 shares (+55.4%) to their portfolio in Q4 2024, for an estimated $10,475,969
RA CAPITAL MANAGEMENT, L.P. added 389,716 shares (+55.4%) to their portfolio in Q4 2024, for an estimated $10,475,566
MONASHEE INVESTMENT MANAGEMENT LLC removed 369,099 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $9,921,381
ADAGE CAPITAL PARTNERS GP, L.L.C. added 327,199 shares (+765.3%) to their portfolio in Q4 2024, for an estimated $8,795,109

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$CDTX Analyst Ratings

Wall Street analysts have issued reports on $CDTX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Citigroup issued a "Outperform" rating on 03/12/2025

To track analyst ratings and price targets for $CDTX, check out Quiver Quantitative's $CDTX forecast page.

Full Release

SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ^® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that it will report its first quarter 2025 financial results and operational highlights after the close of the U.S. financial markets on Thursday, May 8, 2025. The Company will host a conference call and webcast at 5:00 PM Eastern Time to discuss the results and provide an update on business operations.

Conference Call Dial-In & Webcast Information

Date:	Thursday, May 8, 2025
Time:	5:00 PM Eastern Time
United States:	1-800-717-1738
International:	1-646-307-1865
Conference ID:	90743
Webcast:	Link

About Cidara Therapeutics
Cidara Therapeutics is using its proprietary Cloudbreak ^® platform to develop novel drug-Fc conjugates (DFCs) comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment (Fc). Cidara’s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA), and the Company announced completion of Phase 2b enrollment in December 2024. Additional DFCs have been developed for oncology and in July 2024 Cidara received IND clearance for CBO421 which is intended to target CD73 in solid tumors. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com .

INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
[email protected]

MEDIA CONTACT:
Michael Fitzhugh
LifeSci Communications
[email protected]